BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions
Preclinical data for BGM1812 supports further development as next-generation amylin analog for obesity treatment
SUZHOU, China, June 23, 2025 /CNW/ -- BrightGene Pharmaceutical Co., Ltd., an international, innovation-driven pharmaceutical company, presented data from two Phase 2 studies for BGM0504, its investigational dual agonist targeting glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR), along with preclinical data for its novel amylin analog, BGM1812, at the 85 th Scientific Conference of the American Diabetes Association (ADA).
Results from two separate Phase 2 studies in BGM0504 demonstrated significant potential for weight management and metabolic risk reduction in individuals with type 2 diabetes (including superiority to semaglutide), and in overweight and obese non-diabetic individuals, respectively. Preclinical data for BGM1812 demonstrated superior receptor activation, robust weight loss and synergistic potential with GLP-1/GIP dual agonism, supporting its development as a next-generation amylin analog for obesity treatment.
"These Phase 2 data highlight the significant, best-in-class potential of BGM0504 as a treatment for type 2 diabetes and obesity, including potential superiority to semaglutide and a strong safety profile, while our preclinical data for BGM1812 support its continued development as a next-generation amylin analog for obesity treatment, underscoring the additional promise in our pipeline," said Dr. Jiandong Yuan, CEO, BrightGene. "Building on our extensive peptide expertise and strong heritage in high-quality, efficient drug development, BrightGene is committed to accelerating innovative therapeutics to help address unmet patient needs in metabolic disease and other important therapeutic areas."
BGM0504 Phase 2 Study in Type 2 Diabetes
This multicenter, randomized, double-blind (placebo-controlled) and open-label (semaglutide positive-controlled) evaluated the pharmacokinetics, safety and efficacy of once-weekly subcutaneous injection of BGM0504 across the primary endpoint, change from baseline in HbA1c at Week 12 of target dose administration, and multiple secondary endpoints including PPG-2h, FPG, body weight, HbA1c and combined HbA1c/body weight targets proportions, HOMA2-B, blood lipids, systolic blood pressure (SBP) and diastolic blood pressure (DBP).
The study enrolled 67 participants with type 2 diabetes between the ages of 18 and 65, 64 received dose after randomization, randomized into five groups: 5mg (n=13), 10mg (n=12), 15mg (n=13), positive-control group (semaglutide; n=16) or placebo (n=13). Enrolled participants included adults with a baseline HbA1c between 7.0% and 10.0%, and a body mass index (BMI) between 19.5 and 35 kg/m 2.
At Week 12 of target dose administration, treatment with BGM0504 resulted in reductions in HbA1c across the three dose groups that were statistically significant compared with the placebo group and greater than treatment with semaglutide, including -1.72% in the 5mg dose group, -1.94% in the 10mg dose group, and -2.48% in 15mg dose group, compared to -1.43% in semaglutide and -0.28% in placebo. Similar results were observed in multiple secondary endpoints, including PPG-2h, FPG, body weight, and HbA1c and combined HbA1c/body weight target proportions, while varying improvement trends were observed in HOMA2-B, blood lipids, SBP and DBP. Most treatment emergent adverse events (TEAEs) were Grade 1 or 2 during the rapid titration stage and gradually tolerated after reaching the target dose. The most common treatment-related gastrointestinal AEs were diarrhea, nausea and abdominal distension; no hypoglycemic or other unexpected adverse reactions occurred.
BGM0504 Phase 2 Study in Obesity
This randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of BGM0504 in 120 Chinese adults with obesity during multiple-dose administration (subcutaneous injection). Enrolled participants included adults with a BMI ≥ 24kg/m 2 (mean BMI at enrollment ≥ 27kg/m 2) with prediabetes and/or at least one obesity-related comorbidity, or adults with obesity (BMI≥ 28kg/m2, mean BMI at enrollment ≥ 30kg/m2). Participants were randomized into four groups: 5 mg (n=30), 10 mg (n=30), 15 mg(n=30), or placebo (n=30). The study consisted of a titration phase (2-6 weeks), 24-week treatment with once-weekly dosing, and a 2-week follow-up.
Study results demonstrated reductions in waist circumference ranging from −8.0 cm to −12.98 cm (p < 0.001), and significant weight reductions ranging from -10.77% to 19.78% (LS means, placebo adjusted). Results also showed improvements in systolic blood pressure ranging from −11.60 to −13.03 mmHg and diastolic blood pressure ranging from −5.98 to −7.50 mmHg (p < 0.05).
Secondary outcomes further supported the efficacy of BGM0504, and all doses were well tolerated with common adverse events.
BGM1812 Preclinical Study
In a preclinical study, BGM1812 demonstrated strong receptor activation with 1.8× and 2.2× increased agonist activity (EC50) at the amylin and calcitonin receptors, respectively, versus petrelintide. The agonist also demonstrated dose-dependent weight loss in 0.012 - 0.12 mg/kg dose range in the diet-induced obese (DIO) rat model.
At 0.04 mg/kg, BGM1812 achieved greater weight reduction than petrelintide. In addition, BGM1812 significantly preserved relative lean mass while reducing relative fat mass. Additionally, the combination of BGM1812 and BGM0504 resulted in greater and more sustained weight loss than either semaglutide+cagrilintide or amycretin in the DIO rat model.
About BGM0504
The peptide hypoglycemic drug BGM0504 injection is a dual agonist of GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) receptors independently developed by BrightGene. BGM0504 can stimulate the downstream pathways of GIP and GLP-1, produce biological effects such as controlling blood sugar, reducing weight and treating non-alcoholic steatohepatitis (NASH), and show potential for the treatment of various metabolic diseases. BGM0504 is currently in Phase 3 trials in China for weight management and type 2 diabetes and has completed a Phase 1 bridging study for weight management in the U.S. To date, BGM0504 has been investigated in more than 1,000 patients and demonstrated superior efficacy and a strong safety profile.
About BGM1812
BGM1812 is a novel amylin analog designed using AI/ML-driven optimization to enhance agonist activities and formulation properties. A potent and ultra long-acting amylin, BGM1812 has the potential to be a once weekly oral tablet.
BrightGene is an international, innovation-driven pharmaceutical company, listed on the Shanghai Stock Exchange, dedicated to developing and manufacturing high-quality therapeutics to address unmet patient needs. Founded in 2001, BrightGene has evolved from an established global leader in high-hurdle generics and biosimilars to developing innovative metabolic and respiratory therapeutics. An established leader in challenging chemistry and conjugation, BrightGene has proprietary, cutting-edge platforms in peptides, siRNA, nanobodies, as well as advanced formulations, and 272 patents. The company remains a global supplier of 15 APIs and 2 drug products to the US and EU. BrightGene is headquartered in China. Additional information is available at .
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
22 minutes ago
- Cision Canada
GFL Environmental Inc. Announces Quarterly Dividend English
VAUGHAN, ON, July 3, 2025 /CNW/ - GFL Environmental Inc. (NYSE: GFL) (TSX: GFL) ("GFL" or the "Company") today announced that the Board of Directors of the Company has declared a cash dividend of US$0.0154 for each outstanding subordinate voting share and multiple voting share of the Company for the second quarter of 2025. The cash dividend will be paid on July 31, 2025 to shareholders of record at the close of business on July 14, 2025. The Company has designated this dividend as an eligible dividend within the meaning of the Income Tax Act (Canada). About GFL GFL, headquartered in Vaughan, Ontario, is the fourth largest diversified environmental services company in North America, providing a comprehensive line of solid waste management services through its platform of facilities throughout Canada and in 18 U.S. states. Across its organization, GFL has a workforce of more than 15,000 employees. Forward Looking Statements This release includes certain "forward-looking statements", which are not guarantees or assurances of future performance. Because forward-looking statements are related to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. GFL undertakes no obligation to publicly update any forward-looking statement, except as required by applicable securities laws. The declaration, timing, amount and payment of any future dividends remains at the discretion of GFL's Board of Directors.
Cision Canada
an hour ago
- Cision Canada
Innovative Molecules Offer Good News in the Fight Against HIV and Other Viral Infections Français
INRS team is exploring the potential of saponins, a group of natural molecules found in many plants LAVAL, QC, July 3, 2025 /CNW/ - Innovative, nontoxic molecules developed by a research team at the Institut national de la recherche scientifique (INRS) could pave the way for new safe and effective antiviral therapies for prevention and treatment purposes. Are there natural compounds with antiviral properties, particularly against the human immunodeficiency virus (HIV) that causes AIDS? Betulinic acid has long been recognized in medical and scientific communities for its antiviral potential. This molecule, found in various plants, is especially abundant in the bark of white birch trees—a common byproduct of the forestry industry. However, the use of betulinic acid and some of its derivatives in medicine has been limited by a major drawback: the molecules are poorly soluble in water. This limits their absorption by the body and complicates their use in medicine. A discovery by INRS Professor Charles Gauthier 's team, part of the INRS-UQAC Joint Research Unit in Sustainable Health, could significantly unlock the potential of this molecule. Their findings * were recently published in Chemistry – A European Journal. Creating a Promising and Novel Molecule In their research, Professor Gauthier's team studied two natural molecules: betulinic acid and echinocystic acid. Both belong to a family of compounds known as triterpenes and share a similar chemical structure. The researchers chemically modified these molecules using a novel, controlled method by attaching a specific sugar called Lewis X. This sugar is structurally similar to those that define human blood groups. The modification resulted in new chimeric compounds known as "saponins." These saponins had never been described in scientific literature before. They offer several advantages for potential antiviral use: they are significantly more water-soluble than triterpenes, they dissolve well in biological environments, and unlike similar substances that can be toxic, they are safe for human cells and mice. Most importantly, they effectively block HIV activity. The team observed that saponins prevent the virus from using certain carbohydrate-specific proteins, known as Lewis-binding proteins, found on immune cells called DC-SIGN and L-SIGN, to spread to CD4+ cells, the main targets of HIV. "Our results show that these are among the most potent monovalent inhibitors ever identified for blocking this HIV transfer mechanism, even when used at very low concentrations," explains INRS Professor Gauthier, who specializes in chemistry of carbohydrates and natural products. He is also a member of the Pasteur Network. HIV, Ebola disease, dengue fever, coronaviruses: the potential is vast These chimeric molecules capable of blocking viral entry into immune cells—a critical step in infection—are a first of their kind. Saponins could serve as a foundation for developing broad-spectrum antiviral agents that block infection at the earliest stage, such as during sexual transmission of HIV. "While it's known that human breast milk contains oligosaccharides that protect infants from HIV infection during early breastfeeding, we are the first to demonstrate that saponins can inhibit HIV entry via DC-SIGN and L-SIGN receptors," says doctoral student in biology at INRS and lead author Oscar Javier Gamboa Marin. "Despite progress in this field, very few studies have focused on inhibiting DC-SIGN and L-SIGN using Lewis-type carbohydrates," he adds. Another promising feature of saponins is their ability to spontaneously form structures called micelles or to integrate into liposomes. This could further enhance their antiviral effectiveness, particularly through improved targeting of virus-infected cells, and holds out promising research potential. Moreover, since DC-SIGN and L-SIGN proteins are also exploited by other dangerous viruses such as Ebola, dengue, and SARS-CoV-2, saponins open new avenues for developing broad-spectrum antiviral agents against these diseases. About the studies* The article entitled Lewis-X-Containing Triterpenoid Saponins Inhibit DC-SIGN- and L-SIGN-Mediated Transfer of HIV-1 Infection was co-authored by Oscar Javier Gamboa Marin, Kurtis Ng, Nitish Verma, Assi Gérard Flavien Yapi, Ralph Pantophlet, and Charles Gauthier. The article entitled Immunological and Toxicological Assessment of Triterpenoid Saponins Bearing Lewis-X- and QS-21-Based Trisaccharides was co-authored by Oscar Javier Gamboa Marin, Yasmine Adda-Bouchard, Balla Sylla, Nitish Verma, Tania Charpentier, Maya Huber, Guillaume Lopez, André Pichette, Alain Lamarre, and Charles Gauthier. This work was made possible thanks to the support of the Natural Sciences and Engineering Research Council of Canada, the Fonds de recherche du Québec, the Armand-Frappier Foundation, and the Swine and Poultry Infectious Diseases Research Center. INRS is an academic institution dedicated exclusively to graduate research and training in strategic sectors in Quebec. Since 1969, as per its mission, it has actively contributed to Quebec's economic, social, and cultural development. INRS ranks first in Quebec in research intensity. It is made up of five interdisciplinary research and training centres located in Quebec City, Montreal, Laval, and Varennes, and Charlevoix, which focus their efforts on strategic sectors: water, earth, and environment (Eau Terre Environnement Research Centre); energy, materials, and telecommunications (Énergie Matériaux Télécommunications Research Centre); urbanization, culture, and society (Urbanisation Culture Société Research Centre); and health and biotechnology (Armand-Frappier Santé Biotechnologie Research Centre), and Ruralités Durables Research Centre (a center currently under development). Its community includes nearly 1,500 members, including students, postdoctoral fellows, faculty members, and staff.
Cision Canada
an hour ago
- Cision Canada
BMO Survey: Summer Travel Spending Heats Up Despite Economic Concerns Français
Canadians plan to spend an average of $3,825 on travel this summer. 59% agree they are opting to travel within Canada to save money. TORONTO, July 3, 2025 /CNW/ - A special report from the BMO Real Financial Progress Index reveals concerns about the cost of living and economic uncertainty have not cooled Canadians' summer travel plans, with 62% planning on spending the same amount or more on vacations and travel this summer compared to 2024. Nearly four-in-five (77%) Canadians plan on travelling this summer, with an average budget of $3,825, which includes the cost of flights, hotels and accommodations, rentals, gas and food. The survey examined how Canadians are preparing for their summer vacation plans and found: 59% are opting to travel within Canada to save money. More than half (55%) have altered their vacation plans due to rising costs and inflation. 46% have reduced their spending throughout the year to afford their summer vacation plans. Nearly a third (32%) admit to compromising their long-term savings to afford travel plans. "Despite economic pressures, Canadians are still planning on making the most of their summer through meaningful experiences such as travel and celebrations with loved ones," said Anthony (Tony) Tintinalli, Head, Specialized Sales, BMO. "At BMO, financial planning means enjoying today while preparing for tomorrow. Whether it's a summer getaway or a special event, we encourage Canadians to work with an advisor and take advantage of convenient planning tools to help you stay on track towards your goals – without missing out on the moments that matter most." "Canadian consumer confidence remains low but is improving," said Sal Guatieri, Senior Economist, BMO. "The U.S. trade war remains a source of anxiety for many Canadian workers and households, but recent progress towards de-escalation, together with a rebound in equity markets, has lifted consumer spirits in April and May. The improved mood likely explains the increased appetite for travel this summer." The BMO Real Financial Progress Index also explores Canadians' summer spending plans and forecasts: Warming Up for Wedding Season: 34% plan on spending the same amount or more on weddings for family and friends this summer compared to last year. Over half (54%) do not plan on spending on weddings for family and friends this summer. Storm of Celebrations and Steady Spending: Two in five (39%) plan on spending the same amount or more on special events, including graduations and showers this summer than they did in 2024. Less than half (48%) do not have plans to spend on special events this summer. Family Activity Budgets Feel the Heat: 29% will spend the same amount or more on summer camps and childcare compared to 2024. 61% have no plans to spend on summer camps and childcare this year. Sawdust and Sunshine: 42% will spend the same amount or more on home renovations. 44% do not have home renovation plans during the summer. Sunny With a Chance of Splurging: Nearly a third (30%) plan on spending the same amount or more for a large purchase including a home, a car, a boat, etc. 57% do not plan on making a large purchase this summer. Investing in Moments with AIR MILES With over three quarters of Canadians reporting increased concerns about the cost of living (78%) and inflation (76%) since the beginning of the year, the survey found many are taking advantage of loyalty programs such as AIR MILES to help with daily expenses and invest in moments. More than half (52%) plan on using points and rewards earned from loyalty programs on groceries, followed by vacations and trips (25%), entertainment including event tickets, dining, etc. (18%), monthly bills (16%) and weddings and special events with family and friends (5% each). More than three-in-five (61%) Canadians say they would prefer investing in experiences over material things. "While some Canadians may be adjusting how they spend this summer, the desire to travel and enjoy meaningful experiences are still on the horizon for many," said Jason Beales, Chief Strategy and Commercial Officer, AIR MILES Reward Program. "With more than half of Canadians choosing experiences over material things, AIR MILES is helping collectors stretch their dollars further – whether that means saving on everyday essentials or turning Miles into unforgettable memories. Our goal is to make it easier for Canadians get more value from their spending and feel good about their financial progress." BMO Helps Canadians Keep Their Budgets Cool for the Summer BMO offers the following tips to help Canadians create and maintain a personalized budget and make real financial progress: Build a budget and regularly review spending and financial statements at least once a month. A separate budget should be created to help save for more expensive plans, such as a vacation, travel, special events or large purchases. Consider redeeming points from rewards programs or loyalty programs such as AIR MILES to help purchase gifts and/or finance travel costs. Assess recurring "hidden" expenses, such as forgotten subscriptions, and cancel those no longer needed or in use. Seek advice from a professional financial advisor or planner to help develop a personalized financial plan according to financial goals, circumstances and obligations, and time horizons. Set up a savings goal and recurring savings transfers into an account – no matter the amount – which will provide a sense of progress and motivation to achieve their savings goals. Clients can build financial literacy, monitor financial plans, and reach financial goals through BMO's innovative digital tools and resources: BMO SmartProgress: This tool helps customers learn more about important personal finance topics and build financial literacy anywhere and at any time. It is a free, online financial education platform featuring customized, interactive content, including videos and tools, on complex financial planning topics including budgeting and credit management, homeownership and investing. BMO CreditView: Customers can quickly and easily check their credit scores and access new tools and advice to manage their credit profile online and on mobile. BMO Insights: Customers get help saving more, monitoring spending and account values, and spotting unusual activity with 25 BMO Insights that provide customers free, quick, and personalized views of their daily spending to help them make informed decisions. Popular online insights include: CashTrack: Using artificial intelligence, these insights monitor customers' cash flows and let them know if they will run out of money in the next seven days. Spend Categorization: These insights notify customers when there has been a significant increase in a specific spending category or if a free trial has expired. BMO Savings Amplifier Account: To help make saving easy and automatic, BMO's new Savings Amplifier Account offers no monthly fees, a competitive interest rate, and unlimited no-fee transfers to other BMO accounts. In addition, its digital Savings Goals feature enables customers to set, track, and manage their financial goals. To learn more about how BMO can help clients make financial progress, visit To learn more about AIR MILES, visit Launched in February 2021, the BMO Real Financial Progress Index is an indicator of how consumers feel about their personal finances and whether they are making financial progress. The index aims to spark dialogue that will help consumers reach their financial goals and to humanize a topic that causes anxiety for many – money. The research detailed in this document was conducted by Ipsos in Canada from March 3 rd to 26 th, 2025. A sample of n=2,500 adults ages 18+ in Canada were collected. To account for recent changes in the economic situation, certain questions were asked again from April 17 th to 20 th, 2025 among a sample of n=2,001 adults ages 18+ in Canada. Quotas and weighting were used to ensure the composition of both samples reflects that of the Canadian population according to census parameters. The surveys have a credibility interval of +/- 2.7 per cent 19 times out of 20, of what the results would have been had all Canadian adults 18+ been surveyed. About BMO Financial Group BMO Financial Group is the seventh largest bank in North America by assets, with total assets of $1.4 trillion as of April 30, 2025. Serving customers for 200 years and counting, BMO is a diverse team of highly engaged employees providing a broad range of personal and commercial banking, wealth management, global markets and investment banking products and services to 13 million customers across Canada, the United States, and in select markets globally. Driven by a single purpose, to Boldly Grow the Good in business and life, BMO is committed to driving positive change in the world, and making progress for a thriving economy, sustainable future, and inclusive society.
